# Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

> **NCT00442325** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 595 (—)

## Conditions studied

- Coronary Arteriosclerosis
- Diabetes Mellitus, Type 2
- Cerebrovascular Accident
- Dyslipidemia
- Peripheral Vascular Disease

## Interventions

- **DRUG:** Atorvastatin (Lipitor)

## Key facts

- **NCT ID:** NCT00442325
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 595 (—)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442325, "Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00442325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*